SEC Form 4 · accession 0001209191-18-025652

KYNTRA BIO, INC. · KYNB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Thomas B Neff

Officer — Chief Executive Officer · Director

Period of report

Apr 17, 2018

Accepted (ET)

Apr 19, 2018 · 8:37 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000921299

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Apr 17, 2018	M	10,320	$3.60	A	2,933,653	D
Common Stock^F1,F2	Apr 17, 2018	S	5,200	$47.94	D	2,928,453	D
Common Stock^F1,F3	Apr 17, 2018	S	13,700	$48.59	D	2,914,753	D
Common Stock^F1,F4	Apr 17, 2018	S	918	$48.54	D	115,908	I	By Family Partnership
Common Stock	Apr 18, 2018	M	10,320	$3.60	A	2,925,073	D
Common Stock^F1,F5	Apr 18, 2018	S	18,100	$48.68	D	2,906,973	D
Common Stock^F1,F6	Apr 18, 2018	S	800	$49.22	D	2,906,173	D
Common Stock^F1,F7	Apr 18, 2018	S	918	$48.60	D	114,990	I	By Family Partnership
Common Stock	holding	—	—		—	19,500	I	By Spouse
Common Stock^F8	holding	—	—		—	60,946	I	See footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F9	$3.60	Apr 17, 2018	M	10,320	D	—	Mar 11, 2019	Common Stock	10,320	423,101	D
Stock Option (Right to Buy)^F9	$3.60	Apr 18, 2018	M	10,320	D	—	Mar 11, 2019	Common Stock	10,320	412,781	D

Explanation of responses

F1Shares sold pursuant to a 10b5-1 plan.
F2The shares were sold at prices ranging from $47.40 to $48.35. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3The shares were sold at prices ranging from $48.40 to $48.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4The shares were sold at prices ranging from $48.20 to $48.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5The shares were sold at prices ranging from $48.15 to $49.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6The shares were sold at prices ranging from $49.15 to $49.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7The shares were sold at prices ranging from $48.15 to $49.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F8The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
F9Fully vested.